Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Gent, Belgium.
Microb Biotechnol. 2009 Jan;2(1):101-13. doi: 10.1111/j.1751-7915.2008.00064.x. Epub 2008 Oct 13.
Arabinoxylan-oligosaccharides (AXOS) are a recently newly discovered class of candidate prebiotics as - depending on their structure - they are fermented in different regions of gastrointestinal tract. This can have an impact on the protein/carbohydrate fermentation balance in the large intestine and, thus, affect the generation of potentially toxic metabolites in the colon originating from proteolytic activity. In this study, we screened different AXOS preparations for their impact on the in vitro intestinal fermentation activity and microbial community structure. Short-term fermentation experiments with AXOS with an average degree of polymerization (avDP) of 29 allowed part of the oligosaccharides to reach the distal colon, and decreased the concentration of proteolytic markers, whereas AXOS with lower avDP were primarily fermented in the proximal colon. Additionally, prolonged supplementation of AXOS with avDP 29 to the Simulator of Human Intestinal Microbial Ecosystem (SHIME) reactor decreased levels of the toxic proteolytic markers phenol and p-cresol in the two distal colon compartments and increased concentrations of beneficial short-chain fatty acids (SCFA) in all colon vessels (25-48%). Denaturant gradient gel electrophoresis (DGGE) analysis indicated that AXOS supplementation only slightly modified the total microbial community, implying that the observed effects on fermentation markers are mainly caused by changes in fermentation activity. Finally, specific quantitative PCR (qPCR) analysis showed that AXOS supplementation significantly increased the amount of health-promoting lactobacilli as well as of Bacteroides-Prevotella and Clostridium coccoides-Eubacterium rectale groups. These data allow concluding that AXOS are promising candidates to modulate the microbial metabolism in the distal colon.
阿拉伯木聚糖低聚糖(AXOS)是一类最近新发现的候选益生元,这取决于它们的结构,它们在胃肠道的不同部位发酵。这可能会影响大肠中蛋白质/碳水化合物的发酵平衡,并因此影响源自蛋白水解活性的潜在有毒代谢物在结肠中的产生。在这项研究中,我们筛选了不同的 AXOS 制剂,以研究它们对体外肠道发酵活性和微生物群落结构的影响。AXOS 的短期发酵实验(平均聚合度(avDP)为 29)允许部分低聚糖到达远端结肠,并降低蛋白水解标志物的浓度,而低 avDP 的 AXOS 主要在近端结肠发酵。此外,将具有 avDP 29 的 AXOS 长时间补充到人类肠道微生物模拟系统(SHIME)反应器中,降低了两个远端结肠隔室中有毒蛋白水解标志物苯酚和对甲酚的水平,并增加了所有结肠隔室中有益短链脂肪酸(SCFA)的浓度(25-48%)。变性梯度凝胶电泳(DGGE)分析表明,AXOS 补充仅略微改变了总微生物群落,这意味着对发酵标志物的观察到的影响主要是由于发酵活性的变化引起的。最后,特定的定量 PCR(qPCR)分析表明,AXOS 补充显著增加了健康促进乳杆菌以及拟杆菌-普雷沃氏菌和梭菌 coccoides-Eubacterium rectale 组的数量。这些数据表明,AXOS 是调节远端结肠微生物代谢的有前途的候选物。